Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

Four fluid-based biomarkers have been developed into diagnostic tests for Alzheimer's
disease (AD) pathology: the ratio of 42 to 40 amino acid-long amyloid β, a marker of plaque …

Introduction This study investigated the diagnostic and disease‐monitoring potential of
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …

The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease …

Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease …

Purpose The development of blood biomarkers that reflect Alzheimer's disease (AD)
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …

The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-
associated tau protein characterizes 80% of all dementia disorders, the most common …

Background There is an unmet need for an accessible, less invasive, cost-effective method
to facilitate clinical trial enrollment and aid in clinical Alzheimer's disease (AD) diagnosis …

Alzheimer's Disease (AD) is a progressive neurodegenerative disease characterized by
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …